You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

Request a visit from your Galafold® (migalastat) Rare Disease Specialist

Find out if Galafold may be an appropriate treatment for your patients with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant. Once you submit your request, a representative will contact you.

Please fill in all fields below and submit your request.

All fields required.

How would you like to be contacted?
Only One Field Required.

Which of the following would you like more information on? (Check all that apply.)

Thank you for your request!
Oops! Something went wrong while submitting the form.

Important safety information AND INDICATION

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse drug reactions reported with Galafold (≥10 %) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.

USE IN SPECIFIC POPULATIONS

There is insufficient clinical data on Galafold use in pregnant women to inform a drug associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4-AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS AND USAGE

Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Please see accompanying Full Prescribing Information.

Connect your patients to
the support they need

Not actual patients
with Fabry disease.

Not actual patients with Fabry disease.

Connect your patients to the support they need

Help patients make Galafold part of their routine

  • The recommended dose of Galafold is 123 mg orally once every other day at the same time of day1
  • Galafold should be taken on an empty stomach1 to ensure optimal absorption
  • Food should not be consumed at least 2 hours before and 2 hours after taking Galafold to give a minimum 4 hours fast1
  • Clear liquids can be consumed during this 4-hour period1:

Water
(plain, carbonated, or flavored)2

Sodas2

Juices
(no-pulp fruit juices like apple and grape)2

Tea and coffee
(no milk or cream)2

INDICATIONS AND USAGE

Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Help patients establish a routine

Establishing a routine for taking Galafold that fits into patients’ lifestyles may help them stay compliant with the prescribed Galafold dosing regimen.

One option to help patients keep track of their Galafold routine is the Galafold® MyDay App. The app will send reminders:

  • Every other day to let them know when it’s a Galafold day
  • Before and after they take Galafold (to inform them when to begin and end fasting)
  • When it’s time for a prescription refill, and more

Apple, the Apple logo, App Store, and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries and regions. Google Play and the Google Play logo are trademarks of Google LLC.

Help patients establish a routine

Establishing a routine for taking Galafold that fits into patients’ lifestyles may help them stay compliant with the prescribed Galafold dosing regimen.

One option to help patients keep track of their Galafold routine is the Galafold® MyDay App. The app will send reminders:

  • Every other day to let them know when it’s a Galafold day
  • Before and after they take Galafold (to inform them when to begin and end fasting)
  • When it’s time for a prescription refill, and more

Apple, the Apple logo, App Store, and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries and regions. Google Play and the Google Play logo are trademarks of Google LLC.

Support with Amicus Assist®

Once prescribed Galafold and enrolled in the program, Amicus Assist will provide patients with a dedicated case manager who will be their point of contact.* The case manager can:

Verify and explain
Insurance coverage

Assist with the
prior authorization process

Help with the
coordination of delivery
of Galafold

Identify possible
financial assistance

Provide ongoing Galafold
support throughout the
treatment journey

Spanish-speaking case
managers are available
upon request

*

Patients must be prescribed Galafold for an approved indication to be eligible for support from Amicus Assist.

Connect with a case manager toll-free at: 1-833-AMICUS-A (1-833-264-2872),
Monday through Friday, from 8AM to 8PM ET.

For more information about Amicus Assist, please visit www.AmicusAssist.com.

Additional information for
patients is available

For patients looking for more information about their treatment, the Galafold patient website is available. Patients can learn more about how Galafold works, hear from other Galafold patients, and access more resources.

VISIT THE GALAFOLD PATIENT WEBSITE

Additional information for patients is available

For patients looking for more information about their treatment, the Galafold patient website is available. Patients can learn more about how Galafold works, hear from other Galafold patients, and access more resources.

VISIT THE GALAFOLD 
PATIENT WEBSITE

Patient advocacy organizations